Natco Pharma Mekaguda facility gets EIR from USFDA
Hyderabad: Drug firm Natco Pharma today said it has received Establishment Inspection Report (EIR) from the US health regulator for its Active Pharmaceutical Ingredient (API) facility in Mekaguda Village, near Hyderabad.
The US Food and Drug Administration (USFDA) conducted the inspection of the facility from August 5, 2019, till August 9 2019.
"Natco Pharma Limited is pleased to announce successful closure of inspection with the receipt of an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the inspection conducted at its Active Pharmaceutical Ingredient (API) facility in Mekaguda Village, near Hyderabad, India, " Natco said in a filing.
The USFDA gives EIR on the closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection.
Natco Pharma is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs).
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at firstname.lastname@example.org Contact no. 011-43720751 To know about our editorial team click here